Zai Lab Ltd (ZLAB)
Zai Lab Ltd. is a biopharmaceutical company whose American depositary receipts are listed on NASDAQ under ZLAB. The company focuses on discovering, developing, and commercializing therapies in oncology, immunology, neuroscience, and infectious diseases. Its marketed portfolio includes Zejula for ovarian cancer, VYVGART for certain autoimmune neuromuscular disorders, NUZYRA for bacterial infections, Optune for glioblastoma, Qinlock for gastrointestinal stromal tumors, Xacduro for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex, and Augtyro for ROS1-positive non-small cell lung cancer. Zai Lab also works through license, development, and commercialization arrangements with several partners, including Tesaro, NovoCure, Deciphera, Paratek Bermuda, argenx, Turning Point Therapeutics, Entasis Therapeutics, Karuna Therapeutics, and Pfizer. Founded in 2013, the company is based in Pudong, China.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ZLAB
|
$22.91
|
-13.3% Downside
|
Fair
|
$33.14
|
25.5% Upside
|
Undervalued
|
Fair
|
0.0%
|
November 10, 2026
|
4.9x
|
6.6x
|
2.965 B
|
2.602 B
|
7.9%
|
86.5%
|
-3.0
|
74.2%
|
